Publication of annual report & accounts for year ending July 2011 and notice of AGM

Highlights from the financial year ended 31 July 2011

New LabSkin™ model to validate antimicrobial claims made on cosmetic ingredients and formulations.

Evocutis plc is now trading under the ticker AIM:EVO.

The directors of the Company are pleased to announce that shareholders approved the resolution earlier today.

Syntopix Group is pleased to provide a business update for the period ended 31 July 2011.

Posting of Circular and Notice of General Meeting

Syntopix provides an update on three opportunities: SYN1113 (for the treatment of acne) and ongoing programmes with Sinclair Pharma and Beiersdorf AG.

Syntopix are pleased to announce a change of registered office.

Dr. Jonathan Cove will resign as a director of the Company, effective from 1 July 2011.

Syntopix is pleased to announce that all resolutions were duly passed by Shareholders at the General Meeting held earlier today.

Syntopix announce subdivision of current issued share capital and notice of General Meeting

An update on three opportunities: SYN1113 (for the treatment of acne) and ongoing programmes with Sinclair Pharma and Beiersdorf AG

Interim Results for the six months ended 31 January 2011.

Syntopix Group Holding(s) in Company

Syntopix Group Holding(s) in Company

All resolutions have been passed.

Syntopix has signed a research agreement with Beiersdorf AG ("Beiersdorf"), an international branded consumer goods company with a focus on skin care.

The Annual Report and Accounts for the year ended 31 July 2010, the Notice of the Annual General Meeting and the Form of Proxy were posted to shareholders on 14 December 2010

On 2 December 2010, a total of 123,790 options over the Company's ordinary shares were granted to Directors pursuant to the Syntopix Executive Share Option Scheme.

Syntopix audited final results for the year ended 31 July 2010.

Syntopix has appointed XCAP Securities Plc as the Company's Broker with immediate effect.

Syntopix has signed a second agreement with Sinclair Pharma plc (LON:SPH) ("Sinclair"), the international speciality pharmaceutical company.

Syntopix Group plc Holding(s) in Company

Syntopix Group Holding(s) in Company

Syntopix announces it has signed an exclusive agreement with a company that is a world leader in marketing home, health and personal care brands

Syntopix has announced that Alan Aubrey will step down as a non-executive director with immediate effect.

Syntopix has signed an agreement with Sinclair Pharma plc, the international specialty pharma company, to work together on the identification of an antimicrobial compound to synergise and augment the activity of a key product for Sinclair

At the Company's General Meeting held today, all the resolutions were duly passed

Syntopix announce details of a proposed fundraising

Syntopix interim results for the six months ended 31 January 2010

Syntopix announces a board restructure.

All resolutions were passed at todays Annual General Meeting.

Syntopix Group plc announces that all resolutions proposed at the Company's Annual General Meeting held today were duly passed.